^
    Apply
    A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (NCT05565378)
    Phase 2
    GlaxoSmithKline
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    10/14/2022
    Primary completion :
    01/17/2025
    Completion :
    01/14/2028
    PD-L1
    |
    PD-L1-H
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) (NCT03739710)
    Phase 2
    GlaxoSmithKline
    Recruiting
    Last update posted :
    06/29/2023
    Initiation :
    01/24/2019
    Primary completion :
    07/08/2025
    Completion :
    07/08/2025
    BRAF
    |
    Yervoy (ipilimumab) • docetaxel • Zejula (niraparib) • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • feladilimab (GSK3359609) • belrestotug (EOS-448) • nelistotug (GSK6097608)